NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT03454451 2023-12-21CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCorvus Pharmaceuticals, Inc.Phase 1 Completed117 enrolled
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT02501473 2020-09-09MK-3475-174Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 Terminated52 enrolled 23 charts